Abstract

BackgroundCardiovascular complications from COVID-19 include myocarditis, acute myocardial infarction, heart failure, and others. Population-level data is lacking about the relationship between COVID-19 and cardiovascular complications; therefore, we conducted a study to examine the incidence of myocarditis, acute myocardial infarction (AMI), heart failure (HF) after COVID-19 infection.MethodsRetrospective cohort study using de-identified data from 50 health systems across the United States. Cohort groups were created using patients ≥18 who were admitted to hospitals for respiratory illness with COVID-19 in 2020 and respiratory illness without COVID-19 for 2020 and 2019. There were 107,699 patients with COVID-19, 77,499 patients with respiratory illness in 2020, and 112,898 patients in 2019. The COVID-19 group was matched to each respiratory illness group by propensity score. Patients with prior specific cardiovascular events such as myocarditis, AMI, HF were excluded. The primary outcome was myocarditis, and secondary outcomes were AMI and HF.ResultsIn the COVID-19 group, 79 (0.12%) patients had new-onset myocarditis compared to 29 (0.04%) patients in the non-COVID-19 control (Pneumonia/flu) group Odd's Ratio (OR), (OR 2.73, CI 95%, 1.78-4.18). In the COVID-19 group, 1512 patients developed HF compared to 2,659 patients in the non-COVID-19 group (OR 0.49, CI 95%, 0.46-0.52). 1125 patients in COVID-19 group had AMI compared to 1243 patients in non-COVID-19 group (OR 0.87, CI 95%, 0.80-0.94).ConclusionCOVID-19 was associated with a 2-3-fold higher risk of myocarditis. Unexpectedly, lower rates of HF diagnosis reflect challenges faced due to the severity of lung disease leading to obscuring physical exam findings required for HF diagnosis and early mortality before a diagnosis of HF was made.

Highlights

  • COVID-19 affects millions of people worldwide and has been declared a pandemic by The World Health Organization in 2020 [1,2]

  • In the COVID-19 group, 1512 patients developed heart failure (HF) compared to 2,659 patients in the non-COVID-19 group. 1125 patients in COVID-19 group had acute myocardial infarction (AMI) compared to 1243 patients in nonCOVID-19 group

  • It is possible that the lower rate of new HF diagnoses may reflect challenges faced due to the severity of lung disease among these patients

Read more

Summary

Introduction

COVID-19 affects millions of people worldwide and has been declared a pandemic by The World Health Organization in 2020 [1,2]. COVID-19-infection has protean manifestations ranging from asymptomatic infection to multi-organ failure and death. A wide range of cardiovascular complications has been linked to COVID-19, including myocarditis, acute myocardial infarction (AMI), heart failure (HF), life-threatening arrhythmias, cardiogenic shock, etc. The cardiac injury ranged from 7% to 17% of hospitalized patients [6,7]. The direct viral injury is postulated via the virus utilizing angiotensin-converting enzyme-2 (ACE2) receptors within cardiac tissue, leading to a COVID-19 induced inflammatory response and increased cytokine storm. Cardiovascular complications from COVID-19 include myocarditis, acute myocardial infarction, heart failure, and others. Population-level data is lacking about the relationship between COVID-19 and cardiovascular complications; we conducted a study to examine the incidence of myocarditis, acute myocardial infarction (AMI), heart failure (HF) after COVID-19 infection

Methods
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.